HCG and Kisspeptin Interaction: Compatible | Peptide Database

Clinical efficacy shown in osteochondrosis, osteoarthritis, and osteoporosis treatment. Supports cartilage maintenance and joint function. Supports bone and connective tissue healing. Increased Ki-67 expression with suppressed apoptosis in young and aged cells. Enhances collagen synthesis in connective tissue. Inhibited MMP-9 synthesis; maintained extracellular matrix integrity.

Join others researching Ondansetron — share findings, ask questions, and learn from real experiences Ondansetron is a selective serotonin 5-HT3 receptor antagonist originally developed and FDA-approved for the prevention of nausea and vomiting caused by chemotherapy, radiation therapy, and surgery. It works by blocking serotonin signaling in both the gut and the brain's chemoreceptor trigger zone, making it one of the most effective and widely prescribed anti-emetics available. In the performance-enhancement and peptide community, ondansetron has become an essential support compound for managing nausea caused by a range of commonly used agents. GLP-1 receptor agonists like semaglutide and tirzepatide are notorious for dose-dependent nausea, particularly during titration phases, and ondansetron is the go-to solution for keeping users compliant with their protocols. It is similarly relied upon for nausea triggered by HCG, nandrolone (Deca/NPP), pramipexole, and various oral compounds that cause gastric distress. The orally disintegrating tablet (ODT) formulation is especially popular because it dissolves on the tongue in seconds and does not require swallowing a pill while actively nauseated. Ondansetron exerts its anti-emetic effects through selective antagonism of serotonin 5-HT3 receptors. These receptors are concentrated in two key areas relevant to nausea: the vagal afferent nerve terminals in the gastrointestinal tract and the chemoreceptor trigger zone (CTZ) in the area postrema of the brainstem. When emetogenic stimuli (chemotherapy, medications, gut irritation) cause enterochromaffin cells in the gut to release large amounts of serotonin, this serotonin activates 5-HT3 receptors on vagal afferents, which transmit nausea signals to the brainstem vomiting center. Ondansetron blocks this signaling pathway at both the peripheral (gut) and central (CTZ) level. Unlike dopamine antagonists such as metoclopramide, ondansetron does not block D2 receptors and therefore does not cause extrapyramidal side effects or prolactin elevation, making it a much cleaner anti-emetic for long-term or repeated use. The drug is metabolized hepatically via CYP3A4 and CYP1A2 and is eliminated with a half-life of approximately 4 hours.